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Abstract 
 
                    Trichilia monadelpha (Thonn) JJ De Wilde (Meliaceae) bark extract is used in African traditional medicine for the 
management of various disease conditions including inflammatory disorders such as arthritis. The present study was undertaken to 
evaluate the anti-inflammatory properties of aqueous (TWE), alcoholic (TAE) and petroleum ether extract (TPEE) of T. monadelpha 
using the 7-day old chick-carrageenan footpad oedema (acute inflammation) and the adjuvant-induced arthritis model in rats (chronic 
inflammation). TWE and TPEE significantly inhibited the chick-carrageenan footpad oedema with maximal inhibitions of 57.79±3.92 
and 63.83±12 respectively, but TAE did not. The reference anti-inflammatory drugs (diclofenac and dexamethasone) inhibited the 
chick-carrageenan-induced footpad oedema, with maximal inhibitions of 64.92±2.03 and 71.85±15.34 respectively. Furthermore, all 
the extracts and the reference anti-inflammatory agents (diclofenac, dexamethasone, methotrexate) inhibited the inflammatory oedema 
associated with adjuvant arthritis with maximal inhibitions of 64.41±5.56, 57.04±8.57, 62.18±2.56%, for TWE, TAE and TPEE 
respectively and 80.28±5.79, 85.75±2.96, 74.68±3.03% for diclofenac, dexamethasone and methotrexate respectively. Phytochemical 
screening of the plant bark confirmed the presence of a large array of plant constituents such as alkaloids, glycosides, flavonoids, 
saponins, steroids, tannins and terpenoids, all of which may be potential sources of phyto-antiinflammatory agents. In conclusion, our 
work suggests that T. monadelpha is a potential source of antiinflammatory agents. 
 
Keywords: Antiinflammatory, Arthritis, Trichilia monadelpha, chick-carrageenan, phyto-antiinflammatory. 
 
 
Introduction 
 
                   During the past two decades, the use of Traditional Medicine/Complementary and Alternative Medicine (TM/CAM) has 
expanded worldwide and has gained popularity. It has enjoyed great popularity not only by its continued use for primary health care 
needs of the poor in developing countries, but has also been used in societies where conventional medicine is predominant in the 
health care system  (Zhang, 2000; WHO, 2002). In Africa, about 80% of the population rely on TM to help meet their health care 
needs (WHO, 2002). In the recent past, the World Health Organization (WHO) has adopted a deliberate policy to encourage the 
advancement and utilization of TM in the primary healthcare delivery system, particularly in developing countries. This policy is 
based on the sound recognition of the role that TM is already playing in the healthcare system of most developing countries, especially 
in Africa, Asia and Latin America (WHO/ICUN/WWF, 1993; Zhang, 2000; Quick et al., 2002) . Indeed, the greater part of TM 
therapy involves the use of plant extracts or their active principles (WHO/ICUN/WWF, 1993; Quick et al., 2002; Vickers and 
Zollman, 1999). Furthermore, conventional drugs such as aspirin (from willow bark), digoxin (from foxglove), quinine (from cinchona 
bark), and morphine (from the opium poppy) originate from plant sources (Farnsworth, 1988; Vickers and Zollman, 1999). Also, 
African plants have long been the source of important nutritional and therapeutic products. For example, coffee originates from 
Ethiopia, Strophanthus species, common to East and West Africa are strong arrow poisons and yield cardenolides for use against 
cardiac insufficiency,  Catharanthus roseus’s (the Madagascar periwinkle) alkaloids are well-known antileukaemic agents. This 
emphasises the need for continuous screening of African plants for medicinal properties (Farnsworth, 1988). Plant medicines have 
become very useful in the management of chronic disease conditions including asthma, eczema, premenstrual syndrome, migraine, 
menopausal symptoms, chronic fatigue, irritable bowel syndrome and arthritis (Vickers and Zollman, 1999). Several plant medicines 
are used in African TM for managing arthritis (Mshana et al., 2000). However, currently, there is insufficient empirical data to provide 
sound phytopharmacological evidence to validate the ethnomedical uses of some tropical African plants for treatment of arthritis, 
hence the choice of T. monadelpha as the subject of this investigation.  
                T. monadelpha (Thonn) JJ De Wilde (Meliaceae) syn. T. heudelotii (Abbiw, 1990) is a medium-sized tree that grows 12-20 
m high and up to 0.4 m in girth (Irvine, 1961). The plant is distributed in deciduous and semi-deciduous secondary forests, often in 
wet places in Cote d'Ivoire, Sierra Leone, Nigeria, Benin, Congo and Ghana (Irvine, 1961). It is commonly called tanduru/tanduro’ in 
Ghana (Abbiw, 1990; Mshana et al., 2000) and ako rere/rere in Nigeria (Odugbemi and Odunayo, 2008). Various parts of the plant, 
especially the bark, are used traditionally in the management of diverse disease conditions. The bark is used to treat gastrointestinal 
complaints, cough, gonorrhoea, syphilis (Irvine, 1961; Lemmens, 2008) and skin ulcer (Abbiw, 1990). The bark is also used as an 
anthelmintic, aphrodisiac, abortifacient, antiplasmodial (Abbiw, 1990; Lemmens, 2008) and as an antiinflammatory and analgesic 
agent in the management of inflammatory conditions including arthritis (Mshana et al., 2000; Lemmens, 2008). Other parts, such as 
the leaves and roots have many other medicinal uses (Lemmens, 2008). 
               To the best of our knowledge, besides its antimalarial (Atindehou et al., 2004) and antimicrobial effects (Aladesanmi and 
Odediran, 2000; Weiss, 2009) all the other ethnomedical uses have not been validated by any empirical scientific studies. The present 
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study therefore sought to utilise animal models of acute (chick carrageenan) and chronic inflammation (adjuvant arthritis) to 
pharmacologically provide the first scientific evidence to support the ethnomedical use of T. monadelpha in the management of 
inflammatory conditions such as arthritis. 
 
 
Materials and Methods 
Plant material 
 
                The stem bark of T. monadelpha was collected from Bomaa in the Brong Ahafo region of Ghana in December, 2007. The 
plant was authenticated by Dr. Kofi Annan of the Department of Pharmacognosy, Faculty of Pharmacy and Pharmaceutical Sciences, 
KNUST, Kumasi where voucher specimen (FP /07/49) has been kept at the herbarium. 
 
Preparation of extract  
 
               The bark was washed with water, chopped into pieces and air-dried for seven days. The dried pieces were pulverized using a 
hammer mill. The powdered material (1800 g) was divided into three portions of 600 g each. The first portion was macerated with 2.0 
L of 70% (v/v) ethanol in a glass-stoppered flask for seventy-two (72) hours. The filtrate from the macerate was concentrated using a 
rotary evaporator and dried in an oven to give a solid, gummy T. monadelpha extract (referred to as Trichilia alcoholic extract, TAE in 
this project). The second portion was infused with 3.0 L of water and warmed for 60 minutes at 90°C. The infusion was filtered to 
obtain a dark-brown solution, which was evaporated over a hot water-bath and later dried in an oven at 55°C until a constant weight 
was obtained. This was finally cooled in a desicator to yield a dark-brown solid, Trichilia water extract (TWE). The third portion (600 
g) was defatted with 2.5 L of petroleum ether (60-80°C) in a glass-stoppered flask for seventy-two (72) hours. The filtrate was 
evaporated at room temperature (28°C) to yield a syrupy mass of Trichilia petroleum ether extract (TPEE). The percentage yield of the 
aqueous, ethanol and petroleum ether extracts were 18.02%, 15.2% and 1.06% respectively. All extracts were kept in a desicator. The 
various plant extracts were screened using simple qualitative methods described by Evans (2009) and Sofowora (1993).  
 
Drugs and chemicals 
 
              Drugs and chemicals used in this research were obtained from the following sources: diclofenac (Troge, Hamburg, Germany), 
dexamethasone and methotrexate (Pharm-Inter, Brussels, Belgium), carrageenan sodium salt (Sigma Chemicals, St. Louis, MO, USA), 
liquid paraffin (BDH, Poole, England), heat-killed Mycobacterium tuberculosis (Ministry of Agriculture, Fisheries and Food, U.K.). 
 
Animals 
 
              Cockerels (Gallus gallus; strain Shaver 579, Akropong Farms, Kumasi, Ghana) were obtained 1-day post-hatch and were 
housed in stainless steel cages (34×57×40 cm3) in groups of 12–13 chicks per cage. The chicks had free access to food (Chick Mash, 
Gafco, Tema, Ghana) and water. Room temperature was maintained at 29 °C, and an overhead incandescent illumination was 
maintained on a 12-h light–dark cycle. Healthy chicks were selected and tested on day 7. Group sample sizes of five were utilized 
throughout the study. Male Sprague-Dawley rats (150–200 g) were purchased from Noguchi Memorial Institute for Medical Research, 
University of Ghana, Legon, Ghana and housed in the animal facility of the Department of Pharmacology, Kwame Nkrumah 
University of Science and Technology (KNUST). The animals were housed in groups of five in stainless steel cages (34×47×18 cm3) 
with soft wood shavings as bedding, fed with normal commercial pellet diet (GAFCO, Tema), given water ad libitum and maintained 
under laboratory conditions (temperature 24-28 C, relative humidity 60-70%, and 12 hour light-dark cycle). All procedures and 
techniques used in this study were in accordance with the National Institute of Health Guidelines for the Care and Use of Laboratory 
Animals (NIH, Department of Health and Human Services publication no. 85-23, revised 1985). All protocols used were approved by 
the Departmental Ethics Committee. 
 
Carrageenan-induced oedema 
 
                The carrageenan-induced oedema in the footpad of chicks (Roach and Sufka, 2003) was used to evaluate the 
antiinflammatory properties of the extracts (TWE, TAE, and TPEE) compared to reference drugs (diclofenac and dexamethasone). 
Chicks were randomly divided into groups of five. Chicks were then randomly selected to perform one of the following study groups: 
control (1 ml tragacanth mucilage); TWE (10, 30, 100 and 300 mg kg-1, p.o.);TAE (10, 30, 100 and 300 mg kg-1, p.o.); TPEE (10, 30, 
100 and 300 mg kg-1, p.o.) diclofenac (10, 30 and 100 mg kg-1, i.p.), and dexamethasone (0.1, 1.0 and 1.0 mg kg-1, i.p.). Initial foot 
volumes were measured by water displacement as described by Fereidoni et al (2000). Inflammation was induced by subplantar 
injection of carrageenan (10 l of a 1% carrageenan in normal saline) into the right footpad of the chicks. While the control groups 
received only the vehicle orally 1 h before carrageenan injection, the drug treated groups were treated with the drugs 30 min for the 
intraperitoneal route (i.p.) and 1 h for the oral route (p.o.) before carrageenan injection. Foot volumes were measured hourly for 5 
hours after carrageenan injection. The oedema component of inflammation was quantified by measuring the difference in foot volume 
before carrageenan injection and at the various time points. The extract was prepared in 2% tragacanth mucilage. Diclofenac, and 
dexamethasone, were dissolved in normal saline, and used as positive controls. Test drugs were prepared such that not more than 1 ml 
of extract and not more than 0.5 ml of reference drug was administered. All drugs were freshly prepared.  
 
Induction of adjuvant-induced arthritis 
 
              Adjuvant arthritis was induced as previously described (Pearson, 1956). Baseline values (day 0) for joint thickness were  
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taken by measuring the dorso-ventral diameter of the rat hind paw joint (McCartney-Francis et al., 2003) for both the ipsilateral and 
contralateral paws using an electronic digital callipers (KTS 150MM, Knighton Tool Supplies, UK) before arthritis was induced by 
intraplantar injection with 0.1 ml Complete Freund’s Adjuvant (CFA) into the right hind paw (ipsilateral paw). The CFA was prepared 
by triturating heat killed Mycobacterium tuberculosis [strains C, DT and PN (mixed) obtained from the Ministry of Agriculture, 
Fisheries and Food, U.K]) in paraffin oil to make a 3 mg ml-1 suspension. The edema component of inflammation was quantified by 
measuring the difference in joint thickness between day 0 and the various time points. Raw scores for the ipsilateral and contralateral 
joint thickness were individually normalized as percentage of change from their values at day 0, and then averaged for each treatment 
group. To study the effect of reference drugs [diclofenac (Diclo), dexamethasone (Dexa), methotrexate (MTX)] and the plant extracts 
(TWE, TAE and TPEE) on established arthritis, drug treatment was started on day 10 with the onset of the polyarthritic phase, and 
ended on day 28. Rats were randomly grouped (n=5) to receive various treatments as follows: 
Group Treatment 
Group 1 Non-arthritic control/IFA (intraplantar injection of 0.1 ml of IFA) 
Group 2 Arthritic control/CFA (intraplantar injection of 0.1 ml CFA)  
Groups 3-6 TWE (30, 100, 300 and 1000 mg kg-1 p.o. respectively) daily 
Groups 7-10 TAE (30, 100, 300 and 1000 mg kg-1 p.o. respectively) daily 
Groups 11-14 TPEE (30-1000 mg kg-1 p.o. respectively) daily, starting from day 10 
Groups 15-17 Dexamethasone (0.1, 0.3 and 1.0 mg kg-1 i.p. respectively) every other day. 
Groups 18-20 Diclofenac (10, 30 and 100 mg kg-1 i.p. respectively) every other day. 
Groups 21-23 Methotrexate (1.0, 0.3 and 1.0 mg kg-1 i.p. respectively) every four days. 
 
Plant extracts were suspended in 2% tragacanth mucilage whilst the reference drugs (diclofenac, dexamethasone and methotrexate) 
were dissolved in normal saline. Test drugs were prepared such that not more than 1 ml of extract and not more than 0.5 ml of 
reference drug was administered. All drugs were freshly prepared.  
 
Data analysis 
 
              To determine treatment effect in the carrageenan-induced oedema and the Adjuvant induced arthritis model, each animal 
served as its own control. The raw scores for right foot volumes and the ipsilateral hind paw joint thickness were individually 
normalized as percentage of change from their values at time 0 and day 0, then averaged for each treatment group in the carrageenan-
induced oedema and the adjuvant- induced arthritis model respectively. The changes were then presented as % increase in foot volume 
and % change in joint thickness respectively. Time-course curves were plotted for each model and subjected to two-way (treatment × 
time) repeated measures analysis of variance (ANOVA) with Bonferroni’s post hoc test. The total foot volume (carrageenan-induced 
oedema) or the total ipsilateral paw joint thickness (Adjuvant-induced arthritis) were calculated in arbitrary units as the area under the 
time – course curve (AUC) and to determine the percentage inhibition for each treatment, the following equation was used.  
100% 


 
control
treatmentcontrol
AUC
AUCAUCinhibition  
Differences in AUCs were analyzed by ANOVA followed by Student-Newman-Keuls’ post hoc test.  
For the dose response curves, the oedema response (AUC) was expressed as percentage (%) of the maximum oedema (AUC of 
control). Doses for 50% of the maximal effect (ED50) for each drug were determined by using an iterative computer least squares 
method, with the following nonlinear regression (three-parameter logistic) equation:  
  XLogEDabaY   50101  
Where, X is the logarithm of dose and Y is the response. Y starts at a (the bottom) and goes to b (the top) with a sigmoid shape. 
The fitted midpoints (ED50s) of the curves were compared statistically using F test (Miller, 2003; Motulsky and Christopoulos, 2003). 
GraphPad Prism for Windows version 5.00 (GraphPad Software, San Diego, CA, USA) was used for all statistical analyses and ED50 
determinations. Data was presented as means ± standard error of mean (s.e.m), n = 5 and P < 0.05 was considered statistically 
significant.  
 
 
 
Results  
 
                The various fractions of the extracts were found to contain plant constituents such as alkaloids, glycosides, flavonoids, 
saponins, steroids, tannins and terpenoids as listed in table 1. 
 
Table 1: Phytochemical components of TWE, TAE and TPEE. Key: + = present; - = not present. ++ = present in high concentration. 
 
 alkaloids tannins saponins steroids flavonoids terpenoids glycosides 
TWE + + + - + - + 
TAE + + + - + + + 
TPEE + - - ++ - + - 
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Carrageenan-induced oedema 
 
                Intradermal injection of 10 µl of 1% carrageenan induced a time-dependent oedema response in the 7-day old chicks that 
peaked between 2-3 hours post carrageenan injection (Figure 1 and 2) (Roach and Sufka, 2003). Two-way ANOVA (treatment x time) 
from the time-course curves and one-way ANOVA from the area under the time course curves (AUCs) (Figures 1 and 2) revealed 
significant antiinflammatory effects for the reference drugs and extracts except the alcoholic extract (TAE), which did not show any 
significant antiinflammatory effect at the doses tested. The reference antiinflammatory agents diclofenac (F3, 96 = 10.74; P < 0.0001) 
and dexamethasone (F3, 96 = 16.81; P < 0.0001) inhibited carregeenan-induced foot oedema at all the doses tested (Figure 1) with 
maximal inhibition of the total oedema by 64.92±2.03 and 71.85±15.34 at 100 and 1 mg kg-1 for diclofenac and dexamethasone 
respectively. On the contrary, TWE (F4, 120 = 7.47; P < 0.0001) and TPEE (F4, 120 = 10.67; P <0.0001) caused inhibition of the total 
oedema (Figure 2) only at higher doses (100 and 300 mg kg-1) with maximal inhibitory effects of 57.79±3.92% and 63.83±12.84% 
respectively at 300 mg kg-1. They did not cause significant inhibition of the inflammatory oedema at 10 and 30 mg kg-1.  
                 Based on ED50 values (Table 2) obtained from dose-response curves (Figure 3), dexamethasone was the most potent 
inhibitor of       the inflammatory oedema. The rank order of potency was dexamethasone (0.10±0.01 mg kg-1) > diclofenac 
(10.79±1.57 mg kg-1) > TPEE (28.90±2.67 01 mg kg-1) > TWE (55.78±6.27 mg kg-1) > TAE (98.13±20.10). Comparing ED50 values, 
TPEE (the most potent plant extract) was about 300 fold less potent than dexamethasone. 
 
Table 2 ED50 values for drugs. Values are means ± s.e.m. (n=5) 
ED50 (mg kg-1) Drug Carrageenan-induced oedema Adjuvant-induced arthritis  
Aqueous extract (TWE) 55.78±6.27. 79.23±2.70 
Alcoholic extract (TAE) 98.13±20.10 93.24±3.43 
Pet. Ether extract (TPEE) 28.90±2.67 98.03.±2.49 
Diclofenac 10.79±0.39 2.55±0.15 
Dexamethasone 0.10±0.01 0.037±0.002 
Methotrexate  0.031±0.002 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Dose-response effects of diclofenac (10-100 mg kg-1, i.p.) (a and b); and dexamethasone (0.1-1.0 mg kg-1, i.p.) (c and d) on 
carrageenan-induced foot oedema in chicks. Left panels show the time course of effects and the right panels show the total oedema 
calculated as area under the time – course curve (AUCs) over the 5 h period. Data is presented as means ± s.e.m (n = 5). ** P < 
0.01; *P < 0.05 compared to vehicle-treated group (two-way ANOVA followed by Bonferroni’s post hoc test). 
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Figure 2: Dose-response effects of TWE (10-300 mg kg-1, p.o.) (a and b); TAE (10-300 mg kg-1, p.o.) (c and d) and TPEE (10-300 
mg kg-1, p.o.) (e and f) on carrageenan-induced foot oedema in chicks. Left panels show the time course of effects and the right 
panels show the total oedema calculated as area under the time – course curve (AUCs) over the 5 h period. Data is presented as 
means ± s.e.m (n = 5). ** P < 0.01; *P < 0.05 compared to vehicle-treated group (two-way ANOVA followed by Bonferroni’s 
post hoc test). 
 
Figure 3: Dose response curves for dexamethasone (0.1-1 mg kg-1 i.p.), diclofenac (10-100 mg kg-1 i.p.), TWE (10-300 mg kg-1 p.o.), 
TAE (10-300 mg kg-1 p.o.) and TPEE (10-300 mg kg-1 p.o.) on carrageenan induced foot oedema in 7-day old chicks. Animal were 
treated 1 hour after carrageenan challenge. Each point represents the mean ± s.e.m. (n = 5). 
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Figure 4: Dose-response effects of dexamethasone (0.1-1 mg kg-1, i.p.) (a and b); diclofenac (10-100 mg kg-1, i.p.) (c and d) and 
methotrexate (0.1-1 mg kg-1, i.p.) (e and f) on ipsilateral joint thickness in the Adjuvant-induced arthritis. Left panels show the 
time course of effects and the right panels show the total oedema calculated as area under the time – course curve (AUCs) during 
the polyarthritic phase (days 10-28). Data is presented as means ± s.e.m (n = 5). *** P < 0.001 ** P < 0.01; *P < 0.05 compared to 
vehicle-treated group (two-way ANOVA followed by Bonferroni’s post hoc test). 
 
Figure 5: Dose-response effects of TWE (30-1000 mg kg-1 p.o.) (a and b); TAE (30-1000 mg kg-1, p.o.) (c and d) and TPEE (30-1000 
mg kg-1, p.o.) (e and f) on ipsilateral foot joint thickness in the Adjuvant-induced arthritis. Left panels show the time course of 
effects and the right panels show the total oedema calculated as area under the time – course curve (AUCs) during the polyarthritic 
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phase (days 10-28). Data is presented as means ± s.e.m (n = 5). *** P < 0.001 ** P < 0.01; *P < 0.05 compared to vehicle-treated 
group (two-way ANOVA followed by Bonferroni’s post hoc test). 
 
 
Figure 6: Dose response curves (inhibition of oedema) for TWE (10-1000 mg kg-1 p.o.) (●), TAE (10-1000 mg kg-1 p.o.) (○), TPEE 
(10-1000 mg kg-1 p.o.) (■), dexamethasone (0.1-1 mg kg-1 i.p.) (▲), diclofenac (10-100 mg kg-1 i.p.) (□) and methotrexate (0.1-1 
mg kg-1 i.p.) (∆) on CFA induced arthritis in rats. Each point represents mean ± s.e.m. (n = 5). 
 
Adjuvant arthritis 
 
               Intraplantar injection of CFA into the right foot pad of rats triggered an inflammatory response characterized by paw 
swelling in both the ipsilateral (injected) and the contralateral (non-injected) paw. The response on the injected paw was biphasic 
consisting of an acute phase characterised by unilateral swelling of the ipsilateral paw which peaked 8 days post CFA inoculation, and 
a subsequent polyarthritic/chronic phase which began by day 12 (Figures 4 and 5) confirmed by the development of inflammatory 
oedema in the contralateral paw. All the reference antiinflammatory agents - diclofenac (F3, 144 = 43.36, P < 0.0001), dexamethasone 
(F3, 144 = 37.07, P < 0.0001) and methotrexate (F3, 144 = 30.03, P < 0.0001) caused very significant inhibitions of the polyarthritic phase 
oedema, as was expected, with maximal inhibitions of 85.75±2.96% at 1 mg kg-1 for dexamethasone, 80.28±5.79% at 100 mg kg-1 for 
diclofenac and 74.68±3.03% at 1 mg kg-1 for methotrexate (Figure 4). Similarly all the plant extracts. TWE (F4, 180 = 14.90 P < 
0.0001), TAE (F4, 180 = 10.36), and TPEE (F4, 180 = 12.08 P < 0.0001) significantly inhibited the polyarthritic phase oedema (Figure 5) 
with maximal inhibitions of  64.41±5.56% at 100 mg kg-1 for TWE, 57.04±8.57% at 1000 mg kg-1 for TAE and 62.18±2.56% at 1000 
mg kg-1 for TPEE. From the AUCs it could be observed that whereas the inhibitory effect of TWE was dose dependent, the effect of 
TAE and TPEE were not dose dependent (Figure 5). 
                    ED50 values (Table 2) obtained from dose-response curves (Figure 6), showed that methotrexate (ED50 = 0.031±0.002) 
and dexamethasone (ED50 = 0.037±0.002) were equipotent in inhibiting the inflammatory oedema associated with the polyarthritic 
phase, but diclofenac (ED50 = 2.55±0.15) was about seventy fold less potent in inhibiting the inflammatory oedema compared to 
dexamethasone and methotrexate. The ED50 values for the extracts (TWE, TAE, and TPEE) did not differ much from each other 
(79.23±2.70, 93.24±3.43, and 98.03±2.49 respectively) (Table 1), however the water extract (TWE) which is the most potent plant 
extract in this model was about 2000 fold less potent than methotrexate and dexamethasone 
 
 
Discussion 
 
                This study focused on the effect of plant extracts from the bark of T. monadelpha in animal models of acute (chick-
carrageenan) and chronic inflammation (adjuvant arthritis). The results from this study clearly demonstrate that extracts from the bark 
of T. monadelpha has antiinflammatory properties in both acute and chronic inflammation.  
                Carrageenan-induced acute footpad oedema in laboratory animals first introduced by Winter et al., (1962) is a model of 
acute inflammation which has been widely used to evaluate non-steroidal antiinflammatory drugs (NSAID) (Di Rosa and Willoughby, 
1971). The mediators involved in carrageenan oedema are released in three distinct phases, an initial release of histamine and 5-HT, a 
second phase mediated by kinins and the third phase highly suspected to be mediated by prostaglandins (Di Rosa et al., 1971). 
Inhibition of carrageenan-induced inflammation has shown to be highly predictive of antiinflammatory drug activity in human 
inflammatory disease (Morris, 2003) and remains an acceptable preliminary screening test for antirheumatic effect. Also, studies have 
shown that intraplantar injection of carrageenan in the 7-day-old chick elicits a quantifiable, reliable and relatively short lasting state 
of oedema, that is differentially attenuated by the administration of typical antiinflammatory compounds (Roach and Sufka, 2003). 
The rat adjuvant arthritis on the other hand, is the most frequently used model of chronic inflammation for screening NSAIDs, steroids 
and immunosuppressive drugs (Weichman, 1989; Crofford et al., 1992; Aota et al., 1996).  
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                In this study, the reference antiinflammatory drugs (diclofenac, dexamethasone and methotrexate) inhibited the oedema 
associated with carrageenan-induced inflammation and the rat adjuvant arthritis. This clearly demonstrates the effectiveness of the 
chick-carrageenan, and the rat adjuvant arthritis models as established pharmacological tools for identifying drugs with potential 
antiinflammatory effects. Diclofenac (an NSAID) is thought to stop inflammation mainly by inhibiting prostaglandin synthesis 
through the inhibition of cyclooxygenase (COX) (Vane and Botting, 1987; Vane and Botting, 1996) whereas dexamethasone (a 
steroidal antiinflammatory drug) inhibits inflammation by regulating the expression of corticosteroid-responsive genes resulting in 
profound effects on the concentration, distribution and function of various inflammatory mediators (e.g. COX, leucocytes, cytokines, 
prostaglandins, thromboxanes and leucotrienes, vascular endothelium) synthesized by various target tissues (Cronstein and 
Weissmann, 1995; Vane and Botting, 1996; Schimmer and Parker, 2001). Methothrexate on the other hand, is a folate antagonist and 
an immunosuppressant, first introduced for the management of malignancies (Cronstein and Weissman, 1995, (Swierkot and 
Szechinski, 2006). It is presently prescribed at lower doses for the treatment of rheumatoid arthritis (Furst and Kremer, 1988; Swierkot 
and Szechinski, 2006). Although various biochemical pathways may be involved in its antiinflammatory actions in rheumatoid 
arthritis, studies to date indicate that the most important actions of low-dose MTX are its effects in increasing adenosine level and 
reducing the proinflammatory while increasing antiinflammatory cytokine levels (Cronstein and Weissmann, 1995; Swierkot and 
Szechinski, 2006). 
                  The inhibition of inflammatory oedema by the plant extracts indicates the presence of compounds capable of inhibiting 
both acute and chronic inflammatory processes. The precise mechanism by which T. monadelpha extracts inhibited inflammation was 
outside the scope of this study, however, a colossal amount of data from natural product research shows that plant constituents such as 
alkaloids, flavonoids, glycosides, terpenoids, steroids and many other secondary plant metabolites may exhibit antiinflammatory 
effects (Calixto et al., 2003; Calixto et al., 2004; Rios, 2008) by their modulatory effects on inflammatory mediators (e.g.  arachidonic 
acid metabolites, peptides, excitatory amino acids, amines), the formation and/or action of second messengers (e.g. cGMP, cAMP, 
various protein kinases and calcium), the expression of transcription factors (e.g. AP-1, NF-kB), and the expression of key pro-
inflammatory molecules such as inducible NO synthase (iNOS), COX, cytokines (e.g. IL-1B, TNF-α), neuropeptides and proteases 
(Calixto et al., 2003; Calixto et al., 2004; Rios, 2008). Phytochemical studies of the plant bark showed it contains alkaloids, tannins, 
saponins, steroids, flavonoids, terpenoids and glycosides. These plant metabolites may be responsible for the antiarthritc effects of T. 
monadelpha extracts, since various plant medicines used for different forms of arthritis have been found to contain similar 
phytochemicals (Ahmed et al., 2005; Mythilypriya et al., 2008; Puratchikody et al., 2011). Also, pharmacological and phytochemical 
studies on the stem bark of some members of the family Meliaceae (e.g. Khaya grandifoliola) used in the traditional management of 
arthritis showed antiinflammatory effects with the major phytochemicals being alkaloids, saponins, and tannins (Abiodun et al., 2009). 
Furthermore Bridelia ferrugenia (Euphorbiaceae) stem bark, which is ethnomedically used to treat arthritis (Mshana et al., 2000) was 
found to contain alkaloids, glycosides, steroids and tannins as the major plant constituents (Adebayo and Ishola, 2009). It can therefore 
be inferred that the presence of such a large array of similar phytochemicals in the stem bark of T. Monadelpha, may be largely 
responsible for the antiarthritic effect, and extensive ethnomedical uses of the plant. 
                  Nevertheless, whereas it is clear that the T. monadelpha extracts are effective in reducing inflammation in adjuvant 
arthritis, it remains uncertain whether this is translated into an improvement in indices of joint integrity such as bone and cartilage 
degradation. Further work is therefore, currently underway to identify the individual molecules responsible for the antiinflammatory 
properties, their mechanism of action, and also, to ascertain their effect on bone and joint integrity. The ethanolic extract did not show 
significant antiinflammatory effect in carrageenan oedema, but inhibited the inflammatory oedema associated with adjuvant arthritis. 
This does not necessarily suggest the absence of compounds with antiinflammatory effect in acute inflammation in the ethanolic 
extract, but rather since crude extracts contain several compounds, which may exhibit varying pharmacological effects in biological 
systems, a cancellation effect involving antiiflammatory and proinflammatory components  may have occurred (Davicino et al., 2010). 
It is also possible that the components capable of inhibiting acute inflammation were present in very small concentrations in the 
alcoholic extract compared with the water and petroleum-ether extracts. 
                  In conclusion, our work suggests that T. monadelpha bark extract is a potential source of antiinflammatory agents and thus 
provides the first pharmacological evidence to support its use in the management of inflammatory conditions in African TM. 
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